Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Access Addressing government policy changes that negatively impact access to care for those living with CLL / SLL is a very important part of our Policy Institute work. We are dedicated to addressing
Targeted therapies have greatly improved survival outcomes for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). For example, Ibrutinib is so effective at controlling CLL / SLL that the overall survival of patients treated with first-line ibrutinib is no different from that of the general population.
In this WebMD article, Dr. Koffman provides practical advice on how patients can receive assistance paying for this expensive and potentially lifesaving therapy.
Our own Dr. Brian Koffman interviewed Dr. Parag Jasani, a consultant hematologist with Royal Free London NHS Trust and University College London Hospitals. They discussed a first-in-human study of an experimental drug, NVG-111, a bispecific T cell engager. NVG-111 binds to ROR1 on cancer cells and CD3 on T cells, bringing the T cell close to the cancer cell so it can kill it.
Our own Dr. Brian Koffman interviewed Dr. Matthew Davids, Associate Director of the Center for Chronic Lymphocytic Leukemia (CLL) at Dana-Farber Cancer Institute. They discussed the results of a new study looking at whether combining the anti-CD20 monoclonal antibody obinutuzumab with the BTK inhibitor acalabrutinib provided any additional survival benefit.
In this interview, our own Dr. Brian Koffman interviewed Dr. John Seymour, Director of the Department of Hematology at Peter MacCallum Cancer Centre & Royal Melbourne Hospital in Melbourne, Australia. They discussed the latest updates to the safety data from the ELEVATE R/R study, which was the first clinical trial to compare acalabrutinib and ibrutinib head-to-head.
Here is your weekly summary of what has been happening this past week of January 2, 2023 in the United States.
CLL Society’s COVID-19 Update for the Week of December 12th, 2022: The update for this week will be abbreviated due to CLL Society staff attending ASH. Numbers have sharply increased this past week and the dominant variants that are not sensitive to Evusheld continue to dominant the variant landscape.
BIPOC Resources for Patients with CLL CLL Society is fiercely committed to supporting all individuals impacted by a chronic lymphocytic leukemia diagnosis, regardless of race, ethnicity, age, gender, sexual orientation, socio-economic
One click to our most popular content.
